QIAGEN N.V. research snapshot
QGEN AI stock analysis currently reads QIAGEN N.V. as a high-quality molecular testing and research tools business with a meaningful consumables base, broad customer relationships, and strong free cash flow. The stock closed at $41.51 on July 10, 2026, implying a market value near $8.58 billion. QIAGEN reported 2025 net sales of $2.09 billion, net income of $424.9 million, and company-defined free cash flow of $453.3 million. Q1 2026 sales rose 2% on a reported basis to $492.3 million, but declined 1% at constant exchange rates, and management reduced its full-year 2026 outlook to about 1% to 2% CER sales growth with adjusted diluted EPS of at least $2.43 CER. The main QGEN AI stock forecast question is whether Sample technologies, QIAcuity, QIAGEN Digital Insights, QIAstat-Dx, and QuantiFERON can restore growth without weakening cash generation or increasing leverage. This page is informational research, not investment advice.
Current price
$41.51 close on July 10, 2026
Market cap
$8.58 billion calculated from $41.51 x 206.801 million shares, with a 0.05% variance versus the reported market cap
AI score
72 / 100
Rating
High-quality molecular testing platform with recurring consumables, but the 2026 growth reset, leverage, and event-driven volatility limit confidence
Trend status
Short-term momentum is strong after a sharp July move, while price remains below the 200-day average
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | QIAGEN sells sample preparation, molecular testing, digital PCR, genomics, bioinformatics, and automation solutions. Q1 2026 consumables and related revenue were about 90% of sales, supporting recurring demand. | High |
| Moat | The moat comes from validated workflows, installed instruments, consumables pull-through, regulatory know-how, proprietary assays, software content, and relationships with more than 500,000 customers. | Medium-high |
| Management | CEO Thierry Bernard and CFO Roland Sackers have focused the portfolio on five growth pillars, completed Genoox and Parse acquisitions, and returned more than $1.1 billion to shareholders. The test is whether returns and acquisitions improve per-share economics after the 2026 growth reset. | Medium |
| Financial trend | FY2025 revenue rose 5.65% to $2.09 billion and net income rose to $424.9 million, while free cash flow was $453.3 million. Q1 2026 revenue grew 2% reported, but fell 1% at CER and free cash flow fell to $54 million from $96 million. | High |
| Valuation | At $41.51, tool-checked valuation was about 21.40x trailing GAAP EPS, 2.58x book value, 20.86x TTM free cash flow per share reported by StockAnalysis, and 5.81% on the listed annual dividend. | High |
| Technical trend | The price is above the 50-day average near $36.22 but below the 200-day average near $44.41. RSI near 67.24 shows strong recent momentum, while the July 9 volume spike makes the move event-sensitive. | Medium-high |
| Risk level | Risk is medium-high because 2026 growth guidance was cut, Q1 cash and investments fell after a $500 million synthetic repurchase, long-term debt was $1.65 billion, and product, regulatory, tariff, and customer funding risks remain. | High |
| AI confidence | The AI research has strong factual support for reported results and business structure, but price ranges depend on product adoption, Q2 execution, margin recovery, and the multiple investors assign to diagnostics growth. | Medium-high |
| Investment certainty | Investment certainty is medium rather than high. The business is understandable and cash generative, but the current price requires evidence that the growth pillars can offset weaker QuantiFERON and cautious U.S. Life Sciences demand. | Medium |
QGEN AI stock forecast
The QGEN AI stock forecast uses a three-year sensitivity exercise around the $41.51 closing price and the company 2026 adjusted EPS floor of $2.43. With 10%, 6%, and 2% annual EPS growth and terminal P/E assumptions of 24x, 19x, and 15x, financial_rigor.py produced reference values of $77.6, $55.0, and $38.7. These are model outputs, not promises or analyst targets. The wide range reflects the uncertainty around growth recovery, leverage, currency, and multiple compression.
$56 to $78
More likely if the five growth pillars return to mid-single-digit or better CER growth, Sample technologies and QIAcuity scale, QDI AI products convert to recurring software revenue, QuantiFERON demand normalizes, and free cash flow supports debt reduction and shareholder returns.
$45 to $58
More likely if QIAGEN delivers a gradual recovery from the 1% to 2% CER 2026 outlook, maintains strong gross margins, and earns a moderate quality-business multiple without a large expansion in leverage.
$34 to $41
More likely if U.S. Life Sciences budgets stay cautious, QuantiFERON immigration testing remains weak, product launches or regulatory clearances slip, tariffs and currency pressure margins, or debt and cash flow concerns compress the multiple below the current level.
QGEN AI technical analysis
QGEN AI technical analysis starts from the $41.51 July 10, 2026 close. StockAnalysis listed a 50-day moving average near $36.22, a 200-day moving average near $44.41, RSI near 67.24, average 20-day volume near 3.12 million shares, and beta near 0.64. ChartMill listed support around $42.05 and $43.05 to $44.41 and resistance around $46.22 to $49.74. Because this static page does not fetch request-time chart data, confirm all levels with a live chart before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $41.51 | StockAnalysis closing quote on July 10, 2026. The close was below the session high of $42.31 after a sharp prior-day move. |
| Near support | $41.40 to $42.05 | The July 10 intraday low was $41.40 and ChartMill listed horizontal support near $42.05. A sustained break would weaken the immediate rebound setup. |
| Deeper support | $37.63 to $38.72 | ChartMill listed a 52-week low near $37.63, while the July 7 close was $38.72. This is a deeper reference zone if the post-news move unwinds. |
| Near resistance | $44.41 to $46.47 | The 200-day moving average near $44.41 and ChartMill resistance around $46.22 to $46.47 are the first trend-repair levels. |
| Higher resistance | $47.45 to $49.74 | ChartMill listed a second resistance zone around $47.45 to $47.99 and horizontal resistance near $49.74. |
| 50-day moving average | About $36.22 | StockAnalysis technical snapshot last checked around July 10, 2026. Price remained above this shorter trend reference. |
| 200-day moving average | About $44.41 | StockAnalysis technical snapshot last checked around July 10, 2026. Price remained below this longer trend reference. |
| Momentum and volume | RSI about 67.24; 20-day volume about 3.12M | Momentum was strong but close to the upper end of neutral territory. July 9 volume reached about 12.66 million shares, far above the recent average. |
| Volatility and invalidation | Beta about 0.64; close below $37.63 | The beta is below the market average, but event-driven gaps can still be material. A sustained close below the deeper support zone weakens the rebound thesis. |
QGEN AI trading strategy
The QGEN AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with live chart checks, position sizing, earnings-calendar review, and fresh filings because QGEN can move on regulatory, product, currency, and acquisition news.
Wait for QGEN to reclaim and hold the roughly $44.41 200-day average, then watch whether price clears the $46.22 to $46.47 resistance zone with volume. Confirm the move with Q2 sales, growth-pillar progress, and cash flow rather than price alone.
A failed reclaim or a close below $41.40 weakens the short-term setup. A break below $37.63 is a broader invalidation reference.
If QGEN holds the $41.40 to $42.05 area, monitor whether the rebound is supported by stable 2026 guidance, improving QuantiFERON trends, Sample technologies growth, and continued QIAcuity and QDI adoption.
Do not average down solely because the price reaches support. Reassess if Q2 guidance, free cash flow, debt, or regulatory milestones deteriorate.
Track CER sales by Sample technologies, Diagnostic solutions, PCR, and Genomics or NGS; adjusted EPS; gross and operating margins; free cash flow; debt; share count; Parse integration; and regulatory progress for QIAstat-Dx panels.
Reduce confidence if growth depends on acquisitions without improving organic demand, if leverage stays elevated, or if adjusted results widen materially from GAAP results.
Investment research summary
Customers pay QIAGEN to turn biological samples into usable molecular information. The company sells the sample preparation, assays, instruments, automation, software, and interpretation layers that help researchers, pharmaceutical companies, and clinical laboratories move from sample to insight.
The moat is a workflow system rather than a single product. Validated protocols, regulatory clearances, installed instruments, consumables pull-through, curated genomic knowledge, and customer relationships can make switching costly. The moat is strongest where QIAGEN controls the full workflow and weakest where tools are interchangeable.
The failure path can begin with a weak quarter and become structural. QIAGEN could lose momentum if research budgets stay constrained, new panels fail to gain adoption, competitors improve faster, regulation delays launches, QuantiFERON demand remains unusually weak, or acquisitions add cost without enough recurring revenue.
Thierry Bernard has led QIAGEN as CEO since 2020 after building molecular diagnostics experience, while Roland Sackers has served as CFO since 2004. Management is allocating capital to automation, digital tools, AI-enabled bioinformatics, targeted acquisitions, dividends, and buybacks. The governance test is whether shareholder returns remain disciplined while debt and integration demands rise.
Molecular diagnostics, precision medicine, single-cell analysis, digital PCR, clinical bioinformatics, and antimicrobial resistance testing support long-term demand for molecular workflows. This is a durable healthcare and research trend, but adoption depends on reimbursement, lab budgets, regulatory clearance, and evidence of better outcomes or lower cost.
The price is not demanding by the standards of a high-growth software company, but it still requires a recovery from the 2026 growth reset. A 21.40x trailing P/E and roughly 5.81% listed dividend yield provide some support, while $1.65 billion of long-term debt, weaker Q1 free cash flow, and the stock price below its 200-day average reduce the margin of safety.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| QGEN closing price | $41.51 on July 10, 2026 | StockAnalysis historical price data | July 12, 2026 |
| Market cap and shares | $8.58B market cap; 206.80M shares | StockAnalysis statistics and market-cap calculation | July 12, 2026 |
| FY2025 revenue and net income | $2.090B revenue; $424.88M net income | QIAGEN investor relations key figures | July 12, 2026 |
| FY2025 free cash flow | $453.28M under QIAGEN definition | QIAGEN 2025 key figures and cash-flow definition | July 12, 2026 |
| Q1 2026 sales and product mix | $492.3M sales; Sample technologies $169.6M; Diagnostics $184.8M | SEC QIAGEN Q1 2026 quarterly report | July 12, 2026 |
| Q1 2026 cash and debt | $646.3M cash; $1.65B long-term debt | SEC QIAGEN Q1 2026 quarterly report | July 12, 2026 |
| 2026 outlook | About 1% to 2% CER sales growth; adjusted diluted EPS at least $2.43 CER | QIAGEN full Q1 2026 results | July 12, 2026 |
| Technical snapshot | 50-day average $36.22; 200-day average $44.41; RSI 67.24; beta 0.64 | StockAnalysis statistics | July 12, 2026 |
| Support and resistance snapshot | Support near $42.05 and $43.05 to $44.41; resistance $46.22 to $49.74 | ChartMill technical analysis | July 12, 2026 |
| 2028 strategy | At least $2B combined annual sales from growth pillars in 2028 | QIAGEN strategy materials | July 12, 2026 |
This QGEN AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
